The challenge of drug delivery to the peritoneum
Peritoneal Cancer is most often a complication of primary cancers of various gastro-intestinal or gynecologic origins. It is usually the last stage of these cancers and all patients die within months. Because of the low perfusion index of the pleura and peritoneum, these organs are hard to reach for an intravenously injected drug. 95% of the patients receive systemic intravenous chemotherapy but less than 5% of the injected chemotherapy reaches the target point. Over 95% of the chemotherapy remains in the patient’s bloodstream, causing well known and sometimes severe side effects.